补气活血汤对乙型肝炎肝硬化门静脉高压患者血流动力学及肝纤维化指标的影响

白志芹; 宋会颖; 吴瑞卿; 高冬; 霍红敏; 杨晶; 陈蜀

doi:10.3969/j.issn.1001-5256.2017.02.013

补气活血汤对乙型肝炎肝硬化门静脉高压患者血流动力学及肝纤维化指标的影响

DOI: 10.3969/j.issn.1001-5256.2017.02.013

保定市清苑区人民医院

详细信息

中图分类号: R259
计量
- 文章访问数: 2226
- HTML全文浏览量: 44
- PDF下载量: 404
- 被引次数: 0
出版历程
- 收稿日期: 2016-09-05
- 出版日期: 2017-02-20

Effect of Buqi Huoxue decoction on hemodynamics and liver fibrosis indices in hepatitis B patients with cirrhotic portal hypertension

The People's Hospital of Qingyuan District

摘要

摘要: 目的观察补气活血汤对乙型肝炎肝硬化门静脉高压患者血流动力学及肝纤维化指标的影响。方法选取2013年12月-2015年8月保定市清苑区人民医院收治的乙型肝炎肝硬化患者79例,将患者随机分为研究组（n=41）和对照组（n=38）。2组患者均给予恩替卡韦（0.5 mg,1次/d）和双环醇片（25 mg/次,3次/d）口服,对照组在此基础上加用普萘洛尔（10 mg/次,3次/d）,研究组加用补气活血汤,疗程均为12周。比较2组患者治疗前及治疗12周后血流动力学及肝纤维化指标的变化。计量资料组间比较采用t检验,计数资料组间比较采用χ2检验。结果治疗12周后,2组患者门静脉内径、脾静脉内径、门静脉血流量均较治疗前下降,门静脉血流速度较治疗前升高,差异均有统计学意义（t值分别为3.847、4.672、3.524、5.237、3.578、3.829、3.468、3.673,P值分别为0.041、0.036、0.047、0.032、0.045、0.042、0.048、0.046）,且与对照组相比,研究组变化幅度更明显[（12.86±2.34）mm vs（13.65±2.45）mm,...
- 肝炎,乙型 /
- 肝硬化 /
- 高血压,门静脉 /
- 补气活血汤
Abstract: Objective To investigate the effect of Buqi Huoxue decoction on hemodynamics and liver fibrosis indices in hepatitis B patients with cirrhotic portal hypertension.Methods A total of 79 patients with hepatitis B cirrhosis who were admitted to The People's Hospital of Qingyuan District from December 2013 to August 2015 were enrolled and randomly divided into study group( 41 patients) and control group( 38 patients).The patients in both groups were given oral entecavir( 0.5 mg,once a day) and bicyclol tablets( 25 mg,three times a day);the patients in the control group were given propranolol( 10 mg,three times a day) in addition,and those in the study group were given Buqi Huoxue decoction in addition.The course of treatment was 12 weeks for both groups.The hemodynamics and liver fibrosis indices were compared between the two groups before treatment and after 12 weeks of treatment.The t- test was used for comparison of continuous data between groups,and the chi- square test was used for comparison of categorical data between groups.Results After 12 weeks of treatment,both groups had significant reductions in diameter of the portal vein,diameter of the splenic vein,and portal vein flow and a significant increase in portal vein blood flow velocity( t = 3.847,4.672,3.524,5.237,3.578,3.829,3.468,and 3.673,P = 0.041,0.036,0.047,0.032,0.045,0.042,0.048,and 0.046),and the study group had significantly greater changes in these parameters compared with the control group( diameter of the portal vein:12.86 ± 2.34 mm vs 13.65 ± 2.45 mm,t = 3.725,P = 0.044;diameter of the splenic vein:9.50 ± 1.26 mm vs 11.15 ± 1.37 mm,t =- 6.672,P = 0.012;portal vein flow:1.23 ± 0.35 L / min vs 1.38 ± 0.44 L / min,t =-3.521,P = 0.047;portal vein blood flow velocity:19.50 ± 4.65 cm / s vs 17.57 ± 2.40 cm / s,t =- 6.225,P = 0.024).After 12 weeks of treatment,both groups had reductions in the four liver fibrosis indices hyaluronic acid,laminin,procollagen type Ⅲ,and collagen typeⅣ,and the study group had significantly greater reductions than the control group( hyaluronic acid:285.2 ± 53.4 μg /L vs 347.5 ± 63.4μg /L,t =- 7.252,P = 0.012;laminin:89.5 ± 25.6 μg /L vs 116.5 ± 29.7 μg /L,t =- 6.503,P = 0.018;procollagen type Ⅲ:63.5± 20.6 μg / L vs 98.7 ± 28.4 μg / L,t =- 5.279,P = 0.031;collagen type Ⅳ:85.5 ± 23.7 μg / L vs 122.5 ± 26.4 μg / L,t =- 6.977,P = 0.015).No patient experienced adverse drug reactions during the treatment.Conclusion Buqi Huoxue decoction can significantly improve hemodynamics and serum hepatic fibrosis indices in patients with cirrhotic portal hypertension.
- hepatitis B /
- liver cirrhosis /
- hypertension /
- portal

HTML全文

参考文献(20)

[1]Experts in combined team of the Major Special Project of Ministry of Science and Technology supported by China's“Twelfth Five-Year Plan”.Management of clinical diagnosis,evaluation,and antiviral therapy for HBV-related cirrhosis[J].J Clin Hepatol,2014,30(2):99-108.(in Chinese)科技部十二五重大专项联合课题组专家.乙型肝炎病毒相关肝硬化的临床诊断、评估和抗病毒治疗的综合管理[J].临床肝胆病杂志,2014,30(2):99-108.

[2]TAN YW,YIN YM,YU XJ,et al.Influence of salvia miltiorrhizae and astragalus membranaceus on hemodynamics and liver fibrosis indexes in liver cirrhotic patients with portal hypertension[J].Chin JIntegr Tradit West Med(Chin),2001,21(5):351-353.(in Chinese)谭友文,殷玉梅,於学军,等.丹参、黄芪对肝硬化门静脉高压患者血流动力学及肝纤维化指标的影响[J].中国中西医结合杂志,2001,21(5):351-353.

[3]Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960.

[4]GUO HJ,TONG XF.Observation of Zeqi decoction on hemodynamics and liver fibrosis indexes in liver cirrhosis patients with portal hypertension[J].Hebei J TCM,2015,37(1):18-21.(in Chinese)郭海军,佟雪飞.泽芪汤对肝硬化门静脉高压症患者血流动力学及肝纤维化指标的影响[J].河北中医,2015,37(1):18-21.

[5]LI TH,JIA LY.Observation of the clinical effects of Gexia Zhuyu Decoction Jiaweifang in patients with chronic hepatitis B cirrhosis[J/CD].Chin J Liver Dis:Electronic Edition,2015,7(2):84-87.(in Chinese)李庭辉,贾利英.膈下逐瘀汤加味用于慢性乙型肝炎肝硬化患者的临床疗效观察[J/CD].中国肝脏病杂志:电子版,2015,7(2):84-87.

[6]SHEN GW,LI Q,LIU Y.Danji Huoxue decoction on serum inflammatory and liver fibrosis degradation indexes in hepatitis B patients with cirrhosis[J].J Changchun Univ Chin Med,2016,32(6):1188-1190.(in Chinese)申广文,李强,刘颖.丹鸡活血汤对乙型肝炎肝硬化患者血清炎症指标及肝纤维化降解指标的影响[J].长春中医药大学学版,2016,32(6):1188-1190.

[7]LI WJ,HOU S,ZHENG EZ.A study of the pharmacology and clinical effect of traditional Chinese medicine Astragalus membranaceus[J].Asia-Pacific Tradit Med,2015,11(8):109-110.(in Chinese)李文娟,侯崧,郑恩志.中药黄芪药理及临床疗效评价研究[J].亚太传统医药,2015,11(8):109-110.

[8]LIU C,LIU P,MU YP,et al.Research development on treatment of Huangqi decoction for chronic liver disease[J].World Chin Med,2015,10(2):157-161.(in Chinese)刘畅,刘平,慕永平,等.黄芪汤治疗慢性肝病研究进展[J].世界中医药,2015,10(2):157-161.

[9]MAI JY,WANG MF,HOU TL,et al.Inhibition of total flavonoids of astragalus on expression of fatty acid translocase and cyclooxygenase 2in rats with DMN-induced liver cirrhosis[J].J Pract Hepatol,2015,18(3):274-277.(in Chinese)麦静愔,汪美凤,候天禄,等.黄芪总黄酮抑制肝硬化大鼠肝组织脂肪酸转位酶和环氧化酶2表达[J].实用肝脏病杂志,2015,18(3):274-277.

[10]LI XT,YAO XX,DING WY,et al.Clinical and experimental study of effects of Radix Angelicae Sinensis on hemodynamics of portal hypertension[J].Chin J Gastroenterol Hepatol,1998,7(2):158-161.(in Chinese)李校天,姚希贤,丁文元,等.当归对肝硬化门脉高压影响的临床与实验研究[J].胃肠病学和肝病学杂志,1998,7(2):158-161.

[11]LI Y,WU WQ,ZHANG YM,et al.The effect of erigeron breviscapus on renal protein kinase C in diabetic rats[J].Chin J Nephrol,2000,16(2):89-91.(in Chinese)李英,吴文清,张益民,等.野黄芪甙原对糖尿病大鼠肾脏蛋白激酶C活性作用的研究[J].中华肾脏病杂志,2000,16(2):89-91.

[12]ZHANG P,LIANG JS.Clinical effect of Astragalus membranaceus-Angelica sinensis mixture combined with low-molecular-weight heparin in treatment of refractory nephrotic syndrome[J].China JChin Mater Med,2005,30(17):1371-1372,1384.(in Chinese)张萍,梁劲松.黄芪当归合剂联用低分子肝素治疗难治性肾病综合征疗效观察[J].中国中药杂志,2005,30(17):1371-1372,1384.

[13]WANG YQ.Anti-fibrosis effect of peach kernel extract and its molecular mechanism[J].J Med Theory Pract,2014,27(15):2015-2016.(in Chinese)王玉清.桃仁提取物抗肝纤维化作用及其分子机制研究[J].医学理论与实践,2014,27(15):2015-2016.

[14]LI WZ,ZHANG XH,HUANG QS.Effect of total flavins in Carthamus tinctorius on liver function and related serological parameters in rats with liver fibrosis[J].Jiangxi J Tradit Chin Med,2014,45(10):46-48.(in Chinese)李伟镇,张旭红,黄清松.红花总黄素对肝纤维化大鼠肝功能和相关血清指标的影响[J].江西中医药,2014,45(10):46-48.

[15]ZHANG W.Effect of Radix Paeoniae Rubra on liver fibrosis factors including ECM[J].Chin J Clin Ration Drug Use,2011,4(5A):74-75.(in Chinese)张巍.赤芍对肝纤维化因子ECM等的影响[J].临床合理用药杂志,2011,4(5A):74-75.

[16]CHEN S,ZHANG Y,LI XS.Effects of Tetramethylpyrazine on expression of TGF-βand Smad 2/3 in hepatic fibrosis in rats[J].Chin J Gastroenterol Hepatol,2013,22(10):970-973.(in Chinese)陈爽,张艳,李孝生.川芎嗪对大鼠肝纤维化转化生长因子β1、Smad 2/3表达的影响[J].胃肠病学和肝病学杂志,2013,22(10):970-973.

[17]ZHU JZ,XU QZ,WANG W,et al.Effects of atractylodes macrocephala on intestinal motility and gut hormones in rats with hepatic cirrhosis[J].Acad J Second Military Med Univ,2005,26(11):1307-1308.(in Chinese)朱金照,许其增,王雯,等.中药白术对肝硬化大鼠肠动力及胃肠激素的影响[J].第二军医大学学报,2005,26(11):1307-1308.

[18]PENG SL.The research progress of saikosaponin d effects and its mechanism[J].J Jilin Med Coll,2014,35(1):66-68.(in Chinese)彭顺利.柴胡皂甙d的作用及其机制的研究进展[J].吉林医药学院学报,2014,35(1):66-68.

[19]CHEN CH,JIN SZ,HAN MZ,et al.Research advances in saikosaponins in treatment of liver cirrhosis[J].Chin J Integr Tradit West Med Dig,2016,24(7):565-567.(in Chinese)陈传慧,金世柱,韩明子,等.柴胡皂甙治疗肝硬化的研究进展[J].中国中西医结合消化杂志,2016,24(7):565-567.

[20]LI HZ,LIU Y,LONG SJ.The influence of Herba Artemisiae capillaris on the UDPGT activity in rat's hepat[J].Chin Tradit Patent Med,2001,23(1):45-47.(in Chinese)黎汉忠,刘义,龙盛京.茵陈对大鼠肝UDP-葡萄糖醛酸转移酶活性的影响[J].中成药,2001,23(1):45-47.

施引文献

资源附件(0)

访问统计